

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 February 2005 (03.02.2005)

PCT

(10) International Publication Number
WO 2005/009459 A1

- (51) International Patent Classification⁷: **A61K 38/17**,
A61P 27/04
- (21) International Application Number:
PCT/US2004/022394
- (22) International Filing Date: 9 July 2004 (09.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
10/621,053 15 July 2003 (15.07.2003) US
- (71) Applicant (for all designated States except US): **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, CA 92612 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BAKHIT, Peter, G.** [US/US]; 21661 Brookhurst #144, Huntington Beach, CA 92646 (US). **OLEJNIK, Orest** [US/US]; 5 Addington Place, Coto De Caza, CA 92679 (US). **GRAHAM, Richard** [US/US]; 5066 Balsawood, Irvine, CA 92612 (US).
- (74) Agents: **JOHNSON, Brent, A.** et al.; c/o Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92612 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2005/009459 A1

(54) Title: OPHTHALMIC COMPOSITIONS COMPRISING TREFOIL FACTOR FAMILY PEPTIDES

(57) Abstract: This invention relates to compositions comprising trefoil family factor peptides which are useful in preventing or treating dry eye by topical administration of the composition to eye of the patient. One aspect of this invention relates to topical ophthalmic compositions comprising a trefoil factor family peptide, and preferably, a mucoadhesive component, as described herein. Another aspect of this invention relates to the use of these compositions to treat or prevent dry eye in a patient.

OPHTHALMIC COMPOSITIONS COMPRISING TREFOIL FACTOR FAMILY PEPTIDES

by

Peter G. Bakhit, Orest Olejnik and Richard Graham

Field of the Invention

The present invention relates to pharmaceutical compositions. In particular, the present invention relates to topical ophthalmic compositions comprising a trefoil factor family peptide.

Background of the Invention

Description of Related Art

Dry eye disease is a general term for a variety of conditions characterized by abnormalities in the tear film, which affects three million people in the United States alone. Dry eye is characterized by symptoms such as a sandy-gritty feeling in the eye, burning, irritation, or a foreign-body sensation that worsens during the day. Patients suffering from dry eye disease complain of mild to severe symptoms, and those with severe symptoms may experience constant and disabling eye irritation, and develop ocular surface epithelial disease and sight-threatening sterile or microbial corneal ulceration.

The tear film consists of an inner mucous layer, a middle aqueous layer which forms the bulk of the tear film, and an outer lipid layer. The aqueous layer is secreted by the lacrimal gland and the accessory lacrimal glands, and the tear fluid is drained by the efferent tear ducts. While the underlying causes of dry eye diseases are largely unknown, it is generally accepted that they are associated with abnormalities in the tear composition or flow, which are

affected by a variety of factors including aqueous layer secretion through lacrimal gland and drainage through the efferent tear passage. In addition to abnormalities in the lacrimal glands, abnormalities in the meibomian glands (which secrete the lipid layer), and abnormalities in drainage through the efferent tear duct passage, changes in mucin composition and mucous viscosity may also affect tear flow [Langer G, et al, *Invest Ophthalmol Vis Sci*, 1999, vol. 40, pp. 2220-2224; Danjo Y, et al, *Invest Ophthalmol Vis Sci*, 1998, vol. 39, pp. 2602-2609; and Paulson FP, et al., *Invest Ophthalmol Vis Sci*, 2002, vol. 43, pp. 3359-3364].

Until recently, the only methods used to treat dry eye disease were topical administration of over-the-counter compositions that serve as artificial tears (such as Refresh® marketed by Allergan, Inc), or surgery to close efferent drainage. Recently, a topical ophthalmic product containing Cyclosporin A, marketed by Allergan Inc., as Restasis®, was introduced, which has shown to be effective in treating many cases of dry eye. However, to maximize the number of options available to the physician and the patient any new and effective treatment for dry eye disease is highly desirable.

Trefoil peptides, or trefoil factor family (TFF) peptides are a class of peptides which comprise a common structural motif, known as the trefoil domain, as part of their structure. The trefoil motif comprises about 20 to about 60 amino acid residues (usually about 40) containing six cysteine residues. The six cysteine residues form three disulfide bridges that complete three loops in the peptide chain so that the roughly 40 residues have a clover-like shape, known as the trefoil domain. TFF-peptides can have one or two trefoil domains per molecule, and may comprise additional amino acid residues which are not part of the trefoil domain. To date, three type of TFF-peptides have been isolated from humans-TFF1 (also known as pS2), TFF2 (also known as SP), and TFF3 (also known as ITF). TFF1 and TFF3 peptides each contain one trefoil domain, while TFF2 peptides contain two trefoil domains. TFF1 and TFF2 peptides are both produced by mucus-producing cells of stomach, while TFF3 peptides are produced by goblet cells of small and large intestine.

All three forms of TFF-peptides are known to be produced in epithelial cells around areas of damage to mucus membrane, suggesting that trefoils have a role in healing injury, particularly to epithelial cells. It is believed that TFF-peptides assist healing by both stabilizing mucus membrane at the injury site and by stimulating repair. It has been shown that TFF-peptides noncovalently link mucin, thus influencing the rheology (e.g. increases viscosity) of mucus gels. [Hauser F, Poulsom R, Chinery R, *et al*, *Proc Natl Acad Sci USA*, 1993, vol. 90, pp. 6961-6965; and Babyatsky MW, deBeaumont M, Thim L, Podolky DK, *Gastroenterology*, 1996, vol. 110, pp. 489-497]. TFF-peptides also appear to be responsible for promoting the migration of epithelial cells to the site of injury, thus stimulating repair. [Göke M, *et al*, *Experimental Cell Research*, 2001, vol 264, pp. 337-344; and Playford RJ, *Journal of the Royal College of Physicians of London*, vol 31, pp. 37-40]

Although there is still a great deal unknown about the role of TFF peptides on the ocular surface, in the lacrimal gland, in the efferent passages, and in surrounding tissue, it is believed that TFF-peptides may be present during healing and other related processes in the eye. Biosynthesis and storage TFF1 and TFF3 peptides, but not TFF2, is known to occur in the human conjunctival epithelium [Langer G, *et al*, *Invest Ophthalmol Vis Sci*, 1999, vol. 40, pp. 2220-2224], and in vitro studies have shown that TFF2 and TFF3 peptides promote the migration of wounded corneal epithelial cells from rabbits [Göke M, *et al*, *Experimental Cell Research*, 2001, vol 264, pp. 337-344]. However, to the best of our knowledge, no direct relationship has been unambiguously established between TFF-peptides and any pathological condition affecting the eye.

As mentioned previously, some cases of dry eye may be related to mucin composition and the rheological properties of the corresponding mucous membrane. Some work has also suggested that TTF-peptide secretion might be influenced by alterations in mucins as they occur in patients with dry eye symptoms [Danjo and Paulson]. However, to the best of our knowledge, there is no direct evidence in any prior art demonstrating that TFF-peptide secretion abnormalities contribute to the symptoms or cause of dry eye disease. In

making the above statements, the applicants make no admission as to whether any of the references cited herein are prior art.

Summary Of The Invention

5

Surprisingly, compositions comprising trefoil family factor peptides will be useful in preventing or treating dry eye by topical administration of the composition to eye of the patient. One aspect of this invention relates to a topical ophthalmic composition comprising a therapeutically effective amount of a trefoil factor family (TFF) peptide. Another aspect of this invention relates to a method of preventing or treating dry eye in a person comprising topically administering to the eye of said person a composition comprising a therapeutically effective amount of a trefoil factor family peptide. Another aspect of this invention relates to a pharmaceutical product comprising a composition having a therapeutically effective concentration of a trefoil factor family peptide which is dispensed from a package suitable for ophthalmic use, wherein the use of the composition for the prevention or treatment of dry eye is indicated thereon.

20

Detailed Description of the Invention

The term trefoil factor family (TFF) peptide as used herein refers to any peptide, whether natural or synthetic, which comprises the trefoil motif described previously herein. That is, the TFF-peptide comprises a residue comprising from 20 to about 60 amino acids, including six cysteine residues. The cysteine residues form disulfide bonds which cause the peptide residue to have a clover-like shape comprising three loops. The methods of preparing of TFF-peptides, such as recombinant expression of peptides and synthetic peptide synthesis, are well known in the art. For example, methods of preparing TFF-peptides are included in the following references: US Pat. No. 6,525,018; Allen, et. al., *J Clin Gastroenterol* 1998; 10 (Suppl 1): S93-S98; Ligumsky, et. al., *Isr J Med Sci* 1986; 22:801-806; Dignass, et. al., *J. Clin. Invest.*, 94, 376-383;

Babyatsky, et. al., *Gastroenterology*, 110, 489-497; Hauser, et. al., *Proc. Natl. Acad. Sci. USA*, vol. 90, pp. 6961-6965, August 1993; WO 02102403; and WO02085402, incorporated herein by reference. A therapeutically effective amount of a TFF-peptide can be determined by a person of ordinary skill in the art without undue experimentation. Although any TFF-peptide can be used in any of the compositions described herein related to this invention, it is preferable that TFF1 or TFF3 be used, and more preferred that TFF1 be used. In compositions of this invention the concentration of the TFF-peptide is preferably from about 0.001% to about 1%. More preferred is a concentration of about 0.01% to about 0.5%, and even more preferred is a concentration of about 0.1% to about 0.2%. In the most preferred embodiment of the invention, the concentration of the TFF-peptide is about 0.15%.

In relation to any of the compositions described herein related to this invention, it is preferable the composition also comprise a mucoadhesive component. With respect to this invention, the term "mucoadhesive" means a natural or synthetic component, including macromolecules, polymers, and oligomers, or mixtures thereof, that can adhere to a subject's mucous membrane. Adhesion of mucoadhesives to the mucous membrane occurs primarily through noncovalent interactions, such as hydrogen bonding and Van der Waal forces (Tabor et al., 1977 *J. Colloid Interface Sci.* 58:2 and Good 1977 *J. Colloid Interface Sci.* 59:398). While not intending to be bound in any way by theory, it is believed that mucoadhesives will be synergistic with TFF-peptides because they provide targeted delivery of the peptides to the mucous membrane by virtue of their adhesion. This synergy will be particularly pronounced in the case of topical ophthalmic administration of a TFF-peptide because of the otherwise short contact time between the TFF-peptide and the surface of the eye. Another advantage of using mucoadhesive agents in the compositions of this invention is that they help to improve the protective layer on the ocular surface. Examples of mucoadhesives for use in the present invention include, but are not limited to, Carbopol®, pectin, alginic acid, alginate, chitosan, hyaluronic acid, polysorbates, such as polysorbate-20, -21, -40, -60, -61, -65, -80, -81, -85; poly(ethyleneglycol), such as PEG-7, -14, -16, -18, -55, -90, -100,

-135, -180, -4, -240, -6, -8, -9, -10, -12, -20, or -32; oligosaccharides and polysaccharides, such as Tamarind seed polysaccharide, gellan, carrageenan, xanthan gum, gum Arabic, and dextran; cellulose esters and cellulose ethers; modified cellulose polymers, such as carboxymethylcellulose, hydroxyethylcellulose, hydroxypropyl methylcellulose, hydroxyethyl ethylcellulose; polyether polymers and oligomers, such as polyoxyethylene; condensation products of poly(ethyleneoxide) with various reactive hydrogen containing compounds having long hydrophobic chains (e.g. aliphatic chains of about 12 to 20 carbon atoms), for example, condensation products of poly(ethylene oxide) with fatty acids, fatty alcohols, fatty amides, polyhydric alcohols; polyether compounds, such as poly(methyl vinyl ether), polyoxypropylene of less than 10 repeating units; polyether compounds, such as block copolymers of ethylene oxide and propylene oxide; mixtures of block copolymers of ethylene oxide and propylene oxide with other excipients, for example poly(vinyl alcohol); polyacrylamide; hydrolyzed polyacrylamide; poly(vinyl pyrrolidone); poly(methacrylic acid); poly(acrylic acid) or crosslinked polyacrylic acid, such as Carbomer®, i.e., a homopolymer of acrylic acid crosslinked with either an allyl ether of pentaerythritol, an allyl ether of sucrose, or an allyl ether of propylene. Preferably, the mucoadhesive component is Tamarind seed polysaccharide, carboxymethylcellulose, hydroxymethylcellulose, Carbopol, hyaluronic acid, xanthan gum, or alginate. The most preferred mucoadhesive component is Tamarind seed polysaccharide, which is a galactoxyloglucan that's extracted from the seed kernel of *Tamarindus Indica*, and can be purchased from TCI America of Portland, OR.

In certain situations it is also advantageous to include a second therapeutically active agent in any of the compositions described herein related to this invention. The second therapeutically active agent could be any drug which might be useful in treating the symptoms of dry eye, or any of its underlying causes. In addition, the second therapeutically active agent could be any drug which is useful in preventing or treating any disease which might occur simultaneously to dry eye disease, whether or not the disease is related. In another useful aspect of this invention, the second therapeutically active

agent could be a drug which is used in topical ophthalmic compositions which might cause, contribute to, or aggravate dry eye disease as a side effect of its use. In this aspect, this invention is useful in reducing or eliminating said side effect.

5 One class of useful second therapeutically active agents in relation to this invention is nucleotide purinergic receptor agonists such as uridine 5'-triphosphate, dinucleotides, cytidine 5'-diphosphosphate, adenosine 5'-diphosphate, P^1 -(cytidine 5'-)-P-(uridine 5'-)tetraphosphates, P^1 , P^4 -di(uridine 5'-)tetraphosphates, or their therapeutically effective analogues or derivatives,
10 which may affect tear secretion, particularly the mucous layer of tears, and thus may have potential in treating dry eye disease. These compounds are described in the following patents, all of which are incorporated herein by reference: U.S. Patent No. 6,555,675; U.S. Patent No. 6,548, 658; U.S. Patent No. 6,436,910; U.S. Patent No. 6,348,589; U.S. Patent No. 6,331,529; U.S. Patent No. 6,323,187;
15 U.S. Patent No. 6,319,908; and U.S. Patent No. 5,900,407.

 Another useful class of compounds that are useful as second therapeutically active agents is nicotinic receptor agonists such as nicotine and its analogs, trans-metanicotine and its analogs, epibatidine and its analogs, pyridol derivatives, piperidine alkaloids such as lobeline and its analogs, certain
20 para-alkylthiophenol derivatives, and imidacloprid and its analogs. These compounds are believed to stimulate secretion of mucin by the conjunctival goblet cells, and thus may be useful in treating dry eye, as disclosed in U.S. Patent No. 6,277,855, which is incorporated herein by reference.

 Another useful class of second therapeutically active agents in relation
25 to this invention is tetracycline, derivatives or analogues of tetracycline, or chemically modified tetracycline. These compounds are believed to have potential in correcting delayed tear clearance, as described in U.S. Patent No. 6,455,583 B1, incorporated herein by reference, which is related to some cases of dry eye.

30 Another class of compounds that are useful as second therapeutically active agents is corticosteroids such as methylprednisolone sodium succinate, prednisolone acetate, prednisolone sodium phosphate, fluorometholone,

fluorometholone acetate, dexamethasone sodium phosphate, hydroxymethyl-progesterone, rimexolane, budesonide, and tixocortol pivalatein, which are believed to be useful in treating dry eye as disclosed in U.S. Patent No. 6,153,607, incorporated herein by reference.

5 Another class of compounds which are useful as second therapeutically active agents is products of human lacrimal gland acinar epithelia such as growth factors or cytokines including the transforming growth factor beta (TGF β), which are disclosed to be useful in treating dry eye in US Patent No. 5,652,209, incorporated herein by reference.

10 Another class useful second therapeutically active agents is androgens or androgen analogues such as 17 α -methyl-17 β -hydroxy-2-oxa-5 α -androstan-3-one, testosterone or testosterone derivatives, 4,5 α -dihydrotestosterone or derivatives, 17 β -hydroxy-5 α -androstane and derivatives, 19-nortestosterone or derivatives, and nitrogen-substituted androgens, which are taught to be useful in
15 treating dry eye disease in the following patents which are incorporated herein by reference, U.S. Patent No. 6,107,289; U.S. Patent No. 5,958,912; U.S. Patent No. 5,688,765; and U.S. Patent No. 5,620,921.

 Another useful class of second therapeutically active agents is cyclosporin and cyclosporin derivatives, such as cyclosporin A, cyclosporin B,
20 cyclosporin C, cyclosporin D, and cyclosporin G.

 In relationship to any of the compositions described herein, it is preferable that an effective amount of buffer be included to maintain the pH from about 6 to about 8, preferably about 7. Buffers used are those known to those skilled in the art, and, while not intending to be limiting, some examples are acetate, borate,
25 carbonate, citrate, and phosphate buffers. Preferably, the buffer comprises borate. An effective amount of buffer necessary for the purposes of this invention can be readily determined by a person skilled in the art without undue experimentation. In cases where the buffer comprises borate, it is preferable that the concentration of the borate buffer be about 0.6%.

30 In any of the compositions related described herein related to this invention, it is preferable for a tonicity agent to be used. Tonicity agents are used in ophthalmic compositions to adjust the concentration of dissolved material to

the desired isotonic range. Tonicity agents are known to those skilled in the ophthalmic art, and, while not intending to be limiting, some examples include glycerin, mannitol, sorbitol, sodium chloride, and other electrolytes. Preferably, the tonicity agent is sodium chloride.

5 In any of the compositions related to the present invention which are described herein, it is preferable for a preservative to be used when the composition is intended for multiple use. There may also be reasons to use a preservative in single use compositions depending on the individual circumstances. The term preservative has the meaning commonly understood in
10 the ophthalmic art. Preservatives are used to prevent bacterial contamination in multiple-use ophthalmic preparations, and, while not intending to be limiting, examples include benzalkonium chloride, stabilized oxychloro complexes (otherwise known as Purite®), phenylmercuric acetate, chlorobutanol, benzyl alcohol, parabens, and thimerosal. Preferably, the preservative is benzalkonium
15 chloride (BAK).

Under certain circumstances, a surfactant might be used in any of the compositions related to this invention which are described herein. The term surfactant used herein has the meaning commonly understood in the art. Surfactants are used to help solubilize the therapeutically active agent or other
20 insoluble components of the composition, and may serve other purposes as well. Anionic, cationic, amphoteric, zwitterionic, and nonionic surfactants may all be used in this invention. For the purposes of this invention, it is preferable that a nonionic surfactant, such as polysorbates, poloxamers, alcohol ethoxylates, ethylene glycol-propylene glycol block copolymers, fatty acid amides,
25 alkylphenol ethoxylates, or phospholipids, is used in situations where it is desirable to use a surfactant.

Another type of compound that might be used in any composition of this invention described herein is a chelating agent. The term chelating agent refers to a compound that is capable of complexing a metal, as understood by those of
30 ordinary skill in the chemical art. Chelating agents are used in ophthalmic compositions to enhance preservative effectiveness. While not intending to be limiting, some useful chelating agents for the purposes of this invention are

edetate salts, like edetate disodium, edetate calcium disodium, edetate sodium, edetate trisodium, and edetate dipotassium.

A particularly preferred embodiment of this invention comprises a trefoil factor family peptide, tamarind seed polysaccharide, about 0.5% sodium
5 chloride, about 0.005% benzalkonium chloride, and about 0.6% of a borate buffer wherein the pH of the composition is adjusted to from about 6 to about 8.

Another aspect of this invention involves a method of preventing or treating dry eye in a person, comprising topically administering to the eye of said person any one of the compositions described herein as related to this
10 invention, which composition comprises a therapeutically effective amount of a trefoil factor family peptide.

Another aspect of this invention involves a pharmaceutical product comprising any one of the compositions described herein as related to this invention, which composition comprises a therapeutically effective
15 concentration of a trefoil factor family peptide, which is dispensed from a package suitable for ophthalmic use, and wherein the use of the composition for the prevention or treatment of dry eye is indicated thereon.

The best mode of making and using the present invention are described in the following examples. These examples are given only to provide direction and
20 guidance in how to make and use the invention, and are not intended to limit the scope of the invention in any way.

Example 1

Compositions related to this invention are prepared by the following procedure. Unless otherwise indicated, all procedural steps are carried out at
25 room temperature.

Part I

TSP is added to purified water at the concentration indicated in the Table 1, and the solution is brought to a boil and maintained at a gentle boil for about 30
30 minutes. The solution is then allowed to cool to room temperature, and water is added to compensate for evaporative loss during boiling. The solution is then

filtered through a 20 micron clarity filter followed by a 0.45 micron sterilizing filter.

Part II

- 5 Each component listed in Table 1 is added in amount needed to provide the indicated concentration to a fixed volume of the solution from part I, in the following order: TFF 1, boric acid, sodium borate decahydrate, sodium chloride, and BAK. After the addition of each component, the mixture is stirred until the solute is completely dissolved before the next component is added. When all of
- 10 the components of the formulation have been added and dissolved, the pH is then adjusted to 7.0 with NaOH or HCl. The solution is then sterile filtered.

Table 1

Component	Function	% (w/v)
TFF 1	TFF-peptide	0.15
Tamarind Seed Polysaccharide (TSP)	Mucoadhesive	0.5
Boric Acid	Buffer	0.6
Sodium Borate Decahydrate	Buffer	0.035
Sodium Chloride	Tonicity Agent	0.53
Benzalkonium Chloride (BAK)	Buffer	0.005
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.0

15

Example 2

A formulation having the composition of Table 2 is prepared according to an analogous procedure to that of Example 1.

Table 2

Component	Function	% (w/v)
TFF 3	TFF-peptide	0.15
Tamarind Seed Polysaccharide (TSP)	Mucoadhesive	0.5
Boric Acid	Buffer	0.6
Sodium Borate Decahydrate	Buffer	0.035
Sodium Chloride	Tonicity Agent	0.53
Benzalkonium Chloride (BAK)	Buffer	0.005
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.0

Example 3

A formulation having the composition of Table 3 is prepared according to
5 an analogous procedure to that of Example 1.

Table 3

Component	Function	% (w/v)
TFF 1	TFF-peptide	0.15
Sodium Carboxymethylcellulose	Mucoadhesive	0.5
Boric Acid	Buffer	0.6
Sodium Borate Decahydrate	Buffer	0.035
Sodium Chloride	Tonicity Agent	0.53
Benzalkonium Chloride (BAK)	Buffer	0.005
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.0

Example 4

A formulation having the composition of Table 4 is prepared according to
10 an analogous procedure to that of Example 1.

Table 4

Component	Function	% (w/v)
TFF 3	TFF-peptide	0.15
Hydroxypropylmethylcellulose	Mucoadhesive	0.5
Boric Acid	Buffer	0.6
Sodium Borate Decahydrate	Buffer	0.035
Sodium Chloride	Tonicity Agent	0.53
Benzalkonium Chloride (BAK)	Buffer	0.005
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.0

Example 5

A formulation having the composition according to Table 5 is prepared according to the method described in US Patent No. 5,981,607, incorporated herein by reference, with the cyclosporin A being added to the castor oil before introducing the oil into the emulsion. An aqueous solution of the trefoil factor family peptide is sterile filtered into the emulsion after the emulsion has cooled.

10 Table 5

Component	Function	% (w/v)
TFF 3	TFF-peptide	0.15
Cyclosporin A	Second Therapeutically Active Agent	0.05
Castor oil	Oil phase	1.25
Polysorbate-80	Surfactant	1.0
Pemulen TR-2	Emulsion stabilizer	0.05
Glycerin	Tonicity agent	2.2
Purified Water		Q.s.
HCl or NaOH	Buffer	adjust to pH 7.4

Example 6

A drop of a composition prepared according to one of Examples 1-5 is added at least once a day to a patient suffering from dry eye disease. Relief of
5 symptoms is experienced and continues for as long as the patient is receiving the treatment.

CLAIMS

What is claimed is:

- 5 1. A topical ophthalmic composition comprising a therapeutically effective amount of trefoil factor family peptide and a mucoadhesive component.
2. The composition of claim 1 wherein the concentration of the trefoil factor family peptide is from about 0.001% to about 1%.
3. The composition of claim 1 wherein the concentration of the trefoil
10 factor family peptide is from about 0.01% to about 0.5%.
4. The composition of claim 1 wherein the concentration of the trefoil factor family peptide is from about 0.1% to about 0.2%.
5. The composition of claim 1 wherein the concentration of the trefoil factor family peptide is about 0.15%.
- 15 6. The composition of claim 1 which further comprises a second therapeutically active agent.
7. The composition of claim 6 wherein the second therapeutically active agent is cyclosporin A.
8. The composition of claim 1 wherein the mucoadhesive component
20 comprises tamarind seed polysaccharide.
9. The composition of claim 1 which comprises tamarind seed polysaccharide, about 0.5% sodium chloride, about 0.005% benzalkonium chloride, and about 0.6% of a borate buffer wherein the pH of the composition is adjusted to from about 6 to about 8.
- 25 10. A method of preventing or treating dry eye in a person comprising topically administering to the eye of said person a composition comprising a therapeutically effective amount of a trefoil factor family peptide and a mucoadhesive component.
11. The method of claim 10 wherein said mucoadhesive component
30 comprises an oligosaccharide or a polysaccharide.
12. The method of claim 10 wherein the concentration of the trefoil factor family peptide is from about 0.001% to about 1%.

13. The method of claim 10 wherein the concentration of the trefoil factor family peptide is from about 0.01% to about 0.5%.
14. The method of claim 10 wherein the concentration of the trefoil factor family peptide is from about 0.1% to about 0.2%.
- 5 15. The method of claim 10 wherein the concentration of the trefoil factor family peptide is about 0.15%.
16. The method of claim 10 wherein said composition further comprises a second therapeutically active agent.
17. The method of claim 16 wherein said second therapeutically active agent
10 is cyclosporin A.
18. The method of claim 11 wherein the mucoadhesive component comprises tamarind seed polysaccharide.
19. The method of claim 11 wherein said composition comprises tamarind seed polysaccharide, about 0.5% sodium chloride, about 0.005% benzalkonium
15 chloride, and about 0.6% of a borate buffer wherein the pH of the composition is adjusted to from about 6 to about 8.
20. A pharmaceutical product comprising a composition having a therapeutically effective concentration of a trefoil factor family peptide and a mucoadhesive component which is dispensed from a package suitable for
20 ophthalmic use, wherein the use of the composition for the prevention or treatment of dry eye is indicated thereon.
21. The product of claim 20 wherein the concentration of the trefoil factor family peptide is from about 0.001% to about 1%.
22. The product of claim 20 wherein the concentration of the trefoil factor
25 family peptide is from about 0.01% to about 0.5%.
23. The product of claim 20 wherein the concentration of the trefoil factor family peptide is from about 0.1% to about 0.2%.
24. The product of claim 20 wherein the concentration of the trefoil factor family peptide is about 0.15%.
- 30 25. The product of claim 20 which further comprises a second therapeutically active agent.

26. The product of claim 25 wherein the second therapeutically active agent is cyclosporin A.
27. The product of claim 20 wherein the mucoadhesive component comprises tamarind seed polysaccharide.
- 5 28. The product of claim 20 wherein said composition comprises tamarind seed polysaccharide, about 0.5% sodium chloride, about 0.005% benzalkonium chloride, and about 0.1% of a borate buffer wherein the pH of the composition is adjusted to from about 6 to about 8.
29. The composition of claim 1 wherein the trefoil family factor peptide is
10 TFF1 or TFF3.
30. The composition of claim 1 wherein the trefoil family factor peptide is TFF1.
31. The method of claim 10 wherein the trefoil family factor peptide is TFF1 or TFF3.
- 15 32. The method of claim 10 wherein the trefoil family factor peptide is TFF1.
33. The method of claim 11 wherein the trefoil family factor peptide is TFF1 or TFF3.
34. The method of claim 11 wherein the trefoil family factor peptide is
20 TFF1.
35. The product of claim 20 wherein the trefoil family factor peptide is TFF1 or TFF3.
36. The product of claim 20 wherein the trefoil family factor peptide is TFF1.
- 25 37. An aqueous composition comprising a trefoil factor family peptide and a second therapeutically active agent, wherein said composition is indicated for topical ophthalmic use in the treatment of dry eye.
38. The composition of claim 37 which further comprises a mucoadhesive.
39. The composition of claim 37 wherein said second therapeutically active
30 agent comprises a nucleotide purinergic receptor agonist; a nicotinic receptor agonist; a tetracycline or a derivative or analogue thereof, or a chemically modified tetracycline; a corticosteroid; a product of human lacrimal gland

acinar epithelia; an androgen or an analogue thereof; or a cyclosporin or a derivative thereof.

40. The composition of claim 39 wherein said second therapeutically active agent comprises a nucleotide purinergic receptor agonist.

5 41. The composition of claim 40 wherein said second therapeutically active agent comprises a uridine 5'-triphosphate, a dinucleotide, a cytidine 5'-diphosphosphate, an adenosine 5'-diphosphate, a P^1 -(cytidine 5')-P-(uridine 5')-tetraphosphate, or a P^1 , P^4 -di(uridine 5')-tetraphosphate.

42. The composition of claim 39 wherein said second therapeutically active agent comprises a nicotinic receptor agonist.

43. The composition of claim 42 wherein said second therapeutically active agent comprises nicotine or an analogue thereof; trans-metanicotine or an analogue thereof; epibatidine or an analogue thereof; a pyridol derivative; a piperidine alkaloid; or imidacloprid or an analogue thereof.

15 44. The composition of claim 39 wherein said second therapeutically active agent comprises a tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline.

45. The composition of claim 39 wherein said second therapeutically active agent comprises a corticosteroid.

20 46. The composition of claim 45 wherein said second therapeutically active agent comprises methylprednisolone sodium succinate, prednisolone acetate, prednisolone sodium phosphate, fluorometholone, fluorometholone acetate, dexamethasone sodium phosphate, hydroxymethyl-progesterone, rimexolane, budesonide, or tixocortol pivalatein.

25 47. The composition of claim 39 wherein said second therapeutically active agent comprises a product of human lacrimal gland acinar epithelia.

48. The composition of claim 47 wherein said second therapeutically active agent comprises transforming growth factor beta.

49. The composition of claim 39 wherein said second therapeutically active agent comprises an androgen, or an androgen analogue.

30 50. The composition of claim 49 wherein said second therapeutically active agent comprises 17α -methyl- 17β -hydroxy-2-oxa- 5α -androstane-3-one;

testosterone or a derivative thereof; 4,5 α -dihydrotestosterone or a derivative thereof; 17 β -hydroxy-5 α -androstane or a derivative thereof; 19-nortestosterone or a derivative thereof; or a nitrogen-substituted androgen.

51. The composition of claim 39 wherein said second therapeutically active
5 agent comprises a cyclosporin or a cyclosporin derivative.

52. The composition of claim 51 wherein said second therapeutically active agent comprises cyclosporin A, cyclosporin B, cyclosporin C, cyclosporin D, or cyclosporin G.

53. The composition of claim 51 wherein said second therapeutically active
10 agent comprises cyclosporin A.

INTERNATIONAL SEARCH REPORT

International Application No.

.../US2004/022394

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K38/17 A61P27/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/151472 A1 (POULSEN STEEN SEIER ET AL) 17 October 2002 (2002-10-17) claim 49	1-53
X	US 6 348 508 B1 (SALAMONE JOSEPH C ET AL) 19 February 2002 (2002-02-19) column 4, paragraphs 2,3; claims 2,18	1-53
Y	EP 0 473 159 A (SENJU PHARMA CO) 4 March 1992 (1992-03-04) claims 1,4	1-53
Y	US 2002/037842 A1 (ELLIS EDWARD J ET AL) 28 March 2002 (2002-03-28) abstract page 10; example 12	1-53
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

5 October 2004

Date of mailing of the international search report

13/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Ludwig, G

INTERNATIONAL SEARCH REPORT

ional Application No
US2004/022394

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 585 987 B1 (FRANSONI MICHELE) 1 July 2003 (2003-07-01) column 6, paragraph 1 - line 6 -----	1-53
Y	EP 0 590 655 A (UNION CARBIDE CHEM PLASTIC) 6 April 1994 (1994-04-06) claims 4,5 -----	1-53

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

/US2004/022394

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002151472 A1	17-10-2002	AU 2156502 A	18-06-2002
		WO 0246226 A2	13-06-2002
		EP 1341817 A2	10-09-2003
		JP 2004515235 T	27-05-2004
		WO 02102399 A2	27-12-2002
		EP 1418930 A2	19-05-2004
		US 2003032585 A1	13-02-2003
US 6348508 B1	19-02-2002	AU 4782201 A	15-10-2001
		CA 2403869 A1	11-10-2001
		CN 1422148 T	04-06-2003
		EP 1267827 A2	02-01-2003
		JP 2003528906 T	30-09-2003
		WO 0174330 A2	11-10-2001
EP 0473159 A	04-03-1992	AT 119387 T	15-03-1995
		CA 2049822 A1	01-03-1992
		DE 69107932 D1	13-04-1995
		DE 69107932 T2	27-07-1995
		DK 473159 T3	22-05-1995
		EP 0473159 A1	04-03-1992
		ES 2069150 T3	01-05-1995
		GR 3015340 T3	30-06-1995
		JP 3256997 B2	18-02-2002
		JP 5004918 A	14-01-1993
		US 5185372 A	09-02-1993
US 2002037842 A1	28-03-2002	US 6281192 B1	28-08-2001
		US 6248360 B1	19-06-2001
		CA 2362498 A1	08-09-2000
		EP 1156809 A1	28-11-2001
		JP 2002538124 A	12-11-2002
		WO 0051619 A1	08-09-2000
		AU 6701101 A	02-01-2002
		BR 0112393 A	08-07-2003
		CA 2413251 A1	27-12-2001
		EP 1294361 A2	26-03-2003
		JP 2003535911 T	02-12-2003
		US 2003039956 A1	27-02-2003
		CN 1441668 T	10-09-2003
		WO 0197851 A2	27-12-2001
		ZA 200210289 A	19-12-2003
US 6585987 B1	01-07-2003	IT MI982461 A1	15-05-2000
		IT MI990064 A1	17-07-2000
		AT 273026 T	15-08-2004
		AU 1295200 A	05-06-2000
		DE 69919379 D1	16-09-2004
		EP 1131105 A1	12-09-2001
		WO 0029030 A1	25-05-2000
EP 0590655 A	06-04-1994	US 5358706 A	25-10-1994
		AT 198145 T	15-01-2001
		CA 2107301 A1	31-03-1994
		DE 69329767 D1	25-01-2001
		DE 69329767 T2	30-08-2001
		EP 0590655 A1	06-04-1994
		JP 2969584 B2	02-11-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

US 2004/022394

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0590655	A	JP 6192130 A US 5645827 A	12-07-1994 08-07-1997